Spotlight on Biotechnology CEO Clay Siegall

Scientists have recently come up with a device in the lab that is capable of mimicking the female reproductive cycle of human beings. The researchers are hopeful that the device made from living tissue will assist a lot in getting new treatments for any medical issue plaguing women. These include endometriosis and fibroids, miscarriages, gynecologic cancers and infertility. The device, dubbed EVATAR, was described in the Nature Communications Journal on Tuesday.

Budget Cuts Proposed For Great Lakes Clean-Up

Proposed budget cuts by the White House to the Environmental Protection Agency as well as other agencies will signal an end to federal spending in the clean-up of Great Lakes. This will involve the axing of work on Asian carp, an invasive species and a health program for the public. The works also offer protection to drinking water from poisonous algae for about 11 million residents living around Lake Erie. The White House has proposed major cuts on most government programs especially those around EPA and numerous other environmental agencies. If Congress passes these budget cuts, it could signify the end of using federal funds to clean up the Great Lakes. There are some Republicans who have joined the Democrats in preserving that money.

About Clay Siegall’s Quest to Change Cancer Therapy

A high number of companies are making inroads in the cancer research field and one of the notable companies is the Seattle Genetics. The company is currently focused on making more advancement in the area of cancer therapy. The tripling of the company’s stock price in a span of five years is enough proof that it is on the right track. Siegall’s expert achievements are as a result of his commitment to concentrate on important researches and diligence on the implementation of most advanced research developments. He has a strong desire to help patients and is keen on finding a way to help lessen their suffering. Seattle Genetics, under the stewardship of Dr. Siegall came up with the first ever antibody-drug conjugates (ADCs) that include ADCETRIS (brentuximab vedotin), which was approved by the FDA in 2011.

Clay Siegall is the CEO of Seattle Genetics and is passionate in the improvement of the lives of cancer patients. He is the current CEO, president and chair of the board of Seattle Genetics. He has been the CEO from 2002.